[Dan Montano]

I believe the question of “will there be an “effective” Cure for Parkinson’s Disease in the next 5 to 10 years” is highly depended upon the question, “What causes Parkinson’s Disease?” It is very difficult to find a treatment, if you do not know what causes the disease.

About 5 years ago a new Hypothesis developed stating that those researches believe Parkinson’s Disease is caused by “vascular dysfunction.” New imaging technologies have shown that people suffering with Parkinson’s Disease, have materially diminished blood flows in the area of the brain, which host the dopamine producing neurons.

FGF-1 is a biological molecule which triggers angiogenesis (the growth of new blood vessels). In animal trials (rodents and monkeys) given Parkinson’s Disease, those animals developed the same movement disorders as humans. Those experimental animals given FGF-1; to trigger new blood vessels growth (angiogenesis) had their Parkinson’s symptoms reverse materially.

We have submitted our Investigative New Drug application (IND) to the US FDA and that application is waiting for us to provide additional animal data. We also submitted in Mexico at their regulatory body (equivalent to the FDA) and they accept our animal data and in February 2020 gave us permission to proceed on the First in the Human Brain Phase I clinical trial in Mexico. COVID-19 lock downs have delayed the start of that trial until now. We have a pathway forward and I hope we will be dosing humans within 90 days. We do not need volunteers at this time, the Mexican hospital is the leading neurology hospital in Latin America and they have enough volunteers now for our Phase I clinical trial to treat Parkinson’s disease. I hope by the end of this year we will know if the molecule is safe in the human brain and if we see any improvements, that were witness in the monkeys with Parkinson’s Disease.

Is there a possible treatment which can “effectively” cure Parkinson’s Disease? Ask me in 12 months; after I have seen the human data from this Phase I.

Dan Montano

[Dan Montano]

Zhittya Genesis Medicine announced in its April Update that it has a regulatory pathway to start its Phase I, Proof of Concept clinical trial to utilize FGF-1 to treat Parkinson’s Disease. Dan Montano CEO of Zhittya Genesis Medicine stated that he hopes by the end of 2020 to have human clinical data if the infusion of FGF-1 into humans is safe and has any benefits for Parkinson’s suffers.